-
European Commission approves Pfizer's Zirabev, a biosimilar to Avastin
21 Feb 2019 11:00 GMT
… , metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or … of the originator biologic medicine, Avastin, which works by inhibiting the …
-
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
17 Jan 2019 07:01 GMT
… in combination with Avastin ®, paclitaxel and carboplatin ( … chemotherapy alone.
About Lung Cancer
According to the … lung cancers. It is estimated that approximately 60 percent of lung cancer … .
About Genentech in Lung Cancer
Lung cancer is a major …
-
EMA committee recommends Roche's Tecentriq in combo with Avastin and chemotherapy to treat metastatic NSCLC
04 Feb 2019 08:38 GMT
… with metastatic non-squamous non-small cell lung cancer (NSCLC). In people with EGFR … Avastin, paclitaxel and carboplatin helped people live significantly longer, compared with Avastin … . NSCLC comprises non-squamous and squamous-cell lung cancer, the squamous form of which …
-
NMPA Accepts New Drug Application for IBI-305, a Biosimilar Product Candidate of Bevacizumab (Avastin®)
29 Jan 2019 07:14 GMT
… product candidate of bevacizumab (Avastin®). This NDA by Innovent … treatment of non-small cell lung cancer (NSCLC), colorectal cancer and … the adoption rate of bevacizumab (Avastin®) is relatively low due … for 80% of all lung cancer cases. The incidence of …
-
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
19 Dec 2018 23:13 GMT
… atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and … Avastin plus carboplatin and paclitaxel (Arm B), or
Avastin … lung cancers. It is estimated that approximately 60 percent of lung cancer …
About Genentech in Lung Cancer
Lung cancer is a …
-
FDA approves Genentech drug for lung cancer
07 Dec 2018 01:28 GMT
… certain type of lung cancer. Genentech said the … in combination with Avastin, paclitaxel and carboplatin … Avastin and chemotherapy helped people live significantly longer compared to Avastin … non-squamous non-small cell lung cancer," said Sandra Horning …
-
Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer
05 Dec 2018 09:24 GMT
… for treating a type of lung cancer, a potential boost to the … lucrative non-small-cell lung cancer (NSCLC), which hits some 85 percent of lung cancer patients … replace revenue from cancer medicines Avastin, Rituxan and Herceptin, whose patents …
-
Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints
13 Dec 2018 00:28 GMT
… a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary … a potential biosimilar to Avastin (Bevacizumab), has met … advanced non-squamous non-small cell lung cancer (NSCLC) and a … important treatment for non-small lung cancer patients. The launch …
-
Roche Holding Ltd (RHHBY) Management on Virtual Pipeline Event 2018 World Conference on Lung Cancer Conference Call (Transcript)
26 Sep 2018 22:13 GMT
… Small-cell lung cancer accounts for about 15% of all lung cancers, … , ROS1-inhibitor-naïve, non-small cell lung cancer patients.
So let … in ROS1-positive non-small cell lung cancer and patients treated … experience, particularly with Avastin. How much success …
-
Roche’s Tecentriq, trailing rival drugs, lifts lung cancer survival
25 Sep 2018 15:15 GMT
… added two months to small-cell lung cancer patients’ lives, according to a … lucrative non-small-cell lung cancer (NSCLC), which hits some 85 percent of lung cancer patients … top sellers, Rituxan, Herceptin and Avastin.
So far, however, Roche’s …
About
© 1995-2019